Fentanyl for breakthrough pain: a systematic review

References

• Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain45(1), 45–48 (1991).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain41(3), 273–281 (1990).
   PubMed Web of Science ®Google Scholar
• Bruera E, MacMillan K, Hanson J et al. The Edmonton staging system for cancer pain: preliminary report. Pain37(2), 203–209 (1989).
   PubMed Web of Science ®Google Scholar
• Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur. J. Cancer34(5), 627–631 (1998).
   PubMed Web of Science ®Google Scholar
• Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat. Rev.24(6), 425–432 (1998).
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Jadad AR. Incident pain. Cancer Surv.21, 17–24 (1994).
   PubMedGoogle Scholar
• Davies A, Zeppetella G, Andersen S et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur. J. Pain DOI: 10.1016/j.ejpain.2010.12.004 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Davies A, Dickman A, Reid C et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J. Pain13(4), 331–338 (2009).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain41(3), 273–281 (1990).
   PubMed Web of Science ®Google Scholar
• Grape S, Schug SA, Lauer S et al. Formulations of fentanyl for the management of pain. Drugs70(1), 57–72 (2010).
   PubMed Web of Science ®Google Scholar
• Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin. Pharmacokinet.8(5), 422–446 (1983).
   PubMed Web of Science ®Google Scholar
• Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology90(2), 576–599 (1999).
   PubMed Web of Science ®Google Scholar
• Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin. Pharmacokinet.31(4), 275–292 (1996).
   PubMed Web of Science ®Google Scholar
• Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology74(1), 53–63 (1991).
   PubMed Web of Science ®Google Scholar
• Henthorn TK, Liu Y, Mahapatro M et al. Active transport of fentanyl by the blood–brain barrier. J. Pharmacol. Exp. Ther.289(2), 1084–1089 (1999).
   PubMed Web of Science ®Google Scholar
• Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br. J. Anaesth.54(8), 871–877 (1982).
   PubMed Web of Science ®Google Scholar
• Waters CM, Avram MJ, Krejcie TC et al. Uptake of fentanyl in pulmonary endothelium. J. Pharmacol. Exp. Ther.288(1), 157–163 (1999).
   PubMed Web of Science ®Google Scholar
• Waters CM, Krejcie TC, Avram MJ. Facilitated uptake of fentanyl, but not alfentanil, by human pulmonary endothelial cells. Anesthesiology93(3), 825–831 (2000).
   PubMed Web of Science ®Google Scholar
• Upton RN, Grant C, Martinez AM et al. Recirculatory model of fentanyl disposition with the brain as the target organ. Br. J. Anaesth.93(5), 687–697 (2004).
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D. Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology101(3), 738–743 (2004).
   PubMed Web of Science ®Google Scholar
• Labroo RB, Paine MF, Thummel KE et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab. Dispos.25(9), 1072–1080 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet.41(9), 661–680 (2002).
   PubMed Web of Science ®Google Scholar
• Shafer SL. More on pharmacokinetics with a pocket calculator. Anesthesiology74(3), 631 (1991).
   PubMedGoogle Scholar
• Zernig G, Issaevitch T, Broadbear JH et al. Receptor reserve and affinity of µ opioid agonists in mouse antinociception: correlation with receptor binding. Life Sci.57(23), 2113–2125 (1995).
   PubMed Web of Science ®Google Scholar
• Sirohi S, Dighe SV, Walker EA et al. The analgesic efficacy of fentanyl: relationship to tolerance and µ-opioid receptor regulation. Pharmacol. Biochem. Behav.91(1), 115–120 (2008).
   PubMed Web of Science ®Google Scholar
• Fine PG, Messina J, Xie F et al. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J. Pain Symptom Manage.40(5), 747–760 (2010).
   PubMed Web of Science ®Google Scholar
• Rauck RL, Tark M, Reyes E et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr. Med. Res. Opin.25(12), 2877–2885 (2009).
   PubMed Web of Science ®Google Scholar
• Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today44(1), 41–54 (2008).
   PubMed Web of Science ®Google Scholar
• Segal T, Hale M, Jhangiani H et al. Patients’ experience with fentanyl effervescent buccal tablets: interim analysis of a long-term, multicenter, open-label study in cancer-related breakthrough pain. J. Pain7(4), 35 (2006).
   Google Scholar
• Farrar JT, Portenoy RK, Berlin JA et al. Defining the clinically important difference in pain outcome measures. Pain88(3), 287–294 (2000).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain113(1–2), 9 (2005).
   PubMed Web of Science ®Google Scholar
• Farrar JT, Polomano RC, Berlin JA et al. A comparison of change in the 0–10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Anesthesiology112(6), 1464–1472 (2010).
   PubMed Web of Science ®Google Scholar
• Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet352(9128), 609–613 (1998).
   PubMed Web of Science ®Google Scholar
• Schulz KF, Chalmers I, Hayes RJ et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA273(5), 408–412 (1995).
   PubMed Web of Science ®Google Scholar
• Darwish M, Hamed E, Messina J. Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy. Perspect. Medicin. Chem.4, 11–21 (2010).
   PubMedGoogle Scholar
• Streisand JB, Varvel JR, Stanski DR et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology75(2), 223–229 (1991).
   PubMed Web of Science ®Google Scholar
• Aronoff GM, Brennan MJ, Pritchard DD et al. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med.6(4), 305–314 (2005).
   PubMed Web of Science ®Google Scholar
• Shaiova L, Lapin J, Manco LS et al. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Support. Care Cancer12(4), 268–273 (2004).
   PubMed Web of Science ®Google Scholar
• Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J. Pain Symptom Manage.30(6), 496–497 (2005).
   PubMed Web of Science ®Google Scholar
• Streisand JB, Busch MA, Egan TD et al. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology88(2), 305–309 (1998).
   PubMed Web of Science ®Google Scholar
• Egan TD, Sharma A, Ashburn MA et al. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology92(3), 665–673 (2000).
   PubMed Web of Science ®Google Scholar
• Lichtor JL, Sevarino FB, Joshi GP et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth. Analg.89(3), 732–738 (1999).
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P et al. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. Clin. J. Pain26(4), 306–309 (2010).
   PubMed Web of Science ®Google Scholar
• Lu J, Bailey P. Dose-related respiratory pharmacology of oral transmucosal fentanyl citrate (OTFC(R)) versus intravenous morphine: a randomized, double-blind, double-dummy study. ASA Annual Meeting Abstracts. Local Anesthesia and Pain99(3A), Abstract A967 (2003).
   Google Scholar
• Sharar SR, Carrougher GJ, Selzer K et al. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J. Burn Care Rehabil.23(1), 27–31 (2002).
   PubMedGoogle Scholar
• Schechter NL, Weisman SJ, Rosenblum M et al. The use of oral transmucosal fentanyl citrate for painful procedures in children. Pediatrics95(3), 335–339 (1995).
   PubMed Web of Science ®Google Scholar
• Schutzman SA, Burg J, Liebelt E et al. Oral transmucosal fentanyl citrate for premedication of children undergoing laceration repair. Ann. Emerg. Med.24(6), 1059–1064 (1994).
   PubMed Web of Science ®Google Scholar
• Sharar SR, Bratton SL, Carrougher GJ et al. A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J. Burn Care Rehabil.19(6), 516–521 (1998).
   PubMedGoogle Scholar
• Robert R, Brack A, Blakeney P et al. A double-blind study of the analgesic efficacy of oral transmucosal fentanyl citrate and oral morphine in pediatric patients undergoing burn dressing change and tubbing. J. Burn Care Rehabil.24(6), 351–355 (2003).
   PubMedGoogle Scholar
• Mahar PJ, Rana JA, Kennedy CS et al. A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries. Pediatr. Emerg. Care23(8), 544–548 (2007).
   PubMed Web of Science ®Google Scholar
• Wheeler M, Birmingham PK, Dsida RM et al. Uptake pharmacokinetics of the fentanyl oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. Paediatr. Anaesth.12(7), 594–599 (2002).
   PubMed Web of Science ®Google Scholar
• Hanks GW, Nugent M, Higgs CM et al. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat. Med.18(8), 698–704 (2004).
   PubMed Web of Science ®Google Scholar
• Christie JM, Simmonds M, Patt R et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J. Clin. Oncol.16(10), 3238–3245 (1998).
   PubMed Web of Science ®Google Scholar
• Shaiova L, Lapin J, Manco LS et al. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Support. Care Cancer12(4), 268–273 (2004).
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD Jr et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain91(1–2), 123–130 (2001).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne R, Coluzzi P et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain79(2–3), 303–312 (1999).
   PubMed Web of Science ®Google Scholar
• Farrar JT, Cleary J, Rauck R et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J. Natl Cancer Inst.90(8), 611–616 (1998).
   PubMed Web of Science ®Google Scholar
• Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J. Pain Symptom Manage.35(5), 563–567 (2008).
   PubMed Web of Science ®Google Scholar
• Jekunen A, Cotterill-Jones C, Dewlan P et al. Dose linearity of inhaled fentanyl (FT) with comparative pharmacokinetics to transmucosal fentanyl (A). J. Clin. Oncol.24(S18), S499 (2006).
   Google Scholar
• Taylor DR, Webster LR, Chun SY et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC®, ACTIQ®). Pain Med.8(3), 281–288 (2007).
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br. J. Cancer96(12), 1828–1833 (2007).
   PubMed Web of Science ®Google Scholar
• Hagen NA, Fisher K, Victorino C et al. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J. Palliat. Med.10(1), 47–55 (2007).
   PubMed Web of Science ®Google Scholar
• Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst. Rev.CD004311 (2006).
   Google Scholar
• Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer84(5), 587–593 (2001).
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Arcuri E. The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. Support. Care Cancer19(3), 435–438 (2010).
   PubMed Web of Science ®Google Scholar
• Bredenberg S, Duberg M, Lennernas B et al.In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur. J. Pharm. Sci.20(3), 327–334 (2003).
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Jiang JG. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin. Pharmacother.8(13), 2011–2016 (2007).
   PubMed Web of Science ®Google Scholar
• Darwish M, Tempero K, Kirby M et al. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin. Pharmacokinet.44(12), 1279–1286 (2005).
   PubMed Web of Science ®Google Scholar
• Darwish M, Tempero K, Kirby M et al. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 µg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin. Ther.28(5), 715–724 (2006).
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P Jr et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J. Clin. Pharmacol.47(3), 343–350 (2007).
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P Jr et al. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J. Clin. Pharmacol.47(1), 56–63 (2007).
   PubMed Web of Science ®Google Scholar
• Darwish M, Kirby M, Jiang JG et al. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 µg in healthy subjects. Clin. Drug Invest.28(1), 1–7 (2008).
   PubMed Web of Science ®Google Scholar
• Lennernas B, Hedner T, Holmberg M et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br. J. Clin. Pharmacol.59(2), 249–253 (2005).
   PubMed Web of Science ®Google Scholar
• Weick JK, Tremmel L, Messina J et al. Finding an appropriate dose of fentanyl effervescent buccal tablets for relief of cancer-related breakthrough pain abstract 2011. J. Clin. Oncol.: ASCO Annual Meeting Proceedings24(18S Part I), 484 (2006).
   PubMed Web of Science ®Google Scholar
• Wertheim M, Jhangiani H, Niebler G et al. Finding an effective dose of fentanyl effervescent buccal tablets: combined results of open-label titration. J. Clin. Oncol.24(18S), S689 (2006).
   Google Scholar
• Slatkin N, Charu V, Niebler G et al. Long-term tolerability of fentanyl effervescent buccal tablets: interim analysis in patients with cancer-related breakthrough pain. J. Clin. Oncol.24(18S), S484 (2006).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Taylor D, Messina J et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain22(9), 805–811 (2006).
   PubMed Web of Science ®Google Scholar
• Webster LR, Taylor D, Peppin J et al. Open-label study of fentanyl effervescent buccal tablets in patients with noncancer pain and breakthrough pain: patient preference assessment. J. Pain7(4), 52 (2006).
   Web of Science ®Google Scholar
• Slatkin NE, Xie F, Messina J et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support. Oncol.5(7), 327–334 (2007).
   PubMedGoogle Scholar
• Portenoy RK, Messina J, Xie F et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr. Med. Res. Opin.23(1), 223–233 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor D, Portenoy R, Messina J et al. A randomized, placebo-controlled study of fentanyl effervescent buccal tablets for relief of breakthrough pain in opioid-tolerant patients with cancer. J. Pain7(4), 2 (2006).
   PubMed Web of Science ®Google Scholar
• Nalamachu S, Xie F, Messina J. Mood, functioning, and quality of life in opioid-tolerant patients with noncancer chronic pain and breakthrough pain: effect of fentanyl buccal tablet (FBT). J. Pain8(4), S43 (2007).
   Google Scholar
• Fine PG, Messina J, Xie F et al. Management of breakthrough pain (BTP) in opioid-tolerant patients with chronic low back pain or neuropathic pain: combined analysis of two randomized, double-blind studies of fentanyl buccal tablet (FBT). J. Pain8(4), S43 (2007).
   Google Scholar
• Simpson D, Messina J, Xie F et al. Management of breakthrough pain in opioid-tolerant patients with chronic low back pain or neuropathic pain: randomized, double-blind studies of efficacy and tolerability of fentanyl buccal tablet (FBT). J. Pain8(4), S41 (2007).
   Google Scholar
• Farrar JT, Michna E, Messina J et al. Impact of fentanyl buccal tablet on both patient and clinician ratings of patient function. J. Pain9(4), 39 (2008).
   Google Scholar
• Zeppetella G, Messina J, Xie F et al. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Pract.10(4), 287–293 (2010).
   PubMed Web of Science ®Google Scholar
• Lennernas B, Frank-Lissbrant I, Lennernas H et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized Phase II study. Palliat. Med.24(3), 286–293 (2010).
   PubMed Web of Science ®Google Scholar
• Passik SD, Messina J, Golsorkhi A et al. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J. Pain Symptom Manage.41(1), 116–125 (2011).
   PubMed Web of Science ®Google Scholar
• Ashburn M, Slevin K, Messina JXF. Fentanyl buccal tablet vs oxycodone immediate-release for the management of breakthrough pain in opioid-tolerant patients with chronic pain: patient disposition and dose titration. J. Pain11(4), S49 (2010).
   Google Scholar
• Fine PG, Narayana A, Passik SD. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. Pain Med.11(7), 1024–1036 (2010).
   PubMed Web of Science ®Google Scholar
• Vasisht N, Gever LN, Tagarro I et al. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med.11(7), 1017–1023 (2010).
   PubMed Web of Science ®Google Scholar
• Vasisht N, Gever LN, Tagarro I et al. Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J. Clin. Pharmacol.50(7), 785–791 (2010).
   PubMed Web of Science ®Google Scholar
• Vasisht N, Gever LN, Tagarro I et al. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin. Drug Invest.29(10), 647–654 (2009).
   PubMed Web of Science ®Google Scholar
• Rauck RL, Tark M, Reyes E et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr. Med. Res. Opin.25(12), 2877–2885 (2009).
   PubMed Web of Science ®Google Scholar
• Dale O. Intranasal administration of opioids/fentanyl – physiological and pharmacological aspects. Eur J. Pain Suppl.4(3), 187 (2010).
   Google Scholar
• Kaasa S, Moksnes K, Nolte T et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J. Opioid Manag.6(1), 17–26 (2010).
   PubMedGoogle Scholar
• Foster D, Upton R, Christrup L et al. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann. Pharmacother.42(10), 1380–1387 (2008).
   PubMed Web of Science ®Google Scholar
• Nave R, Sides EH, Colberg T, Lophaven SO, Meng X, Lahu G, Schmitt H. Higher systemic bioavailability and faster absorption of intranasal fentanyl spray (INFS) compared to ACTIQ (OTFC) in healthy subjects. Eur. J. Pain13, S206 (2009).
   Google Scholar
• Fisher A, Watling M, Smith A et al. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int. J. Clin. Pharmacol. Ther.48(2), 138–145 (2010).
   PubMed Web of Science ®Google Scholar
• Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics after administration of 100ug intranasal fentanyl spray (1 dose vs. 2 doses) in non-elderly and elderly healthy subjects. Eur. J. Pain13, S207 (2009).
   Google Scholar
• Nave R, Sides EH, Colberg T et al. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline. Eur. J. Pain13, S207 (2009).
   Google Scholar
• Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schnmitt H. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with common cold. Eur. J. Pain13, S55–S285 (2009).
   Google Scholar
• Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J. Pain Symptom Manage.20(4), 253–258 (2000).
   PubMed Web of Science ®Google Scholar
• Colberg T, Nolte T, Oronska A et al. Titration of intranasal fentanyl for breakthrough pain in patients with cancer: evidence for dose proportionality vs. background analgesia. Ann. Oncol.19(Suppl. 8), 257–258 (2009).
   Google Scholar
• Kaasa S, Marchesini C, Kaczmarek Z et al. Tolerability and safety of intranasal fentanyl treatment for breakthrough pain in patients with cancer: four-month follow-up. Ann. Oncol.19(Suppl. 8), 257 (2009).
   Google Scholar
• Nolte T, Marchesini C, Oronska A et al. Efficacy of intranasal fentanyl for breakthrough pain in patients with cancer: results of a Phase III trial. Ann. Oncol.19(Suppl. 8), 254 (2009).
   Google Scholar
• Christrup LL, Foster D, Popper LD et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin. Ther.30(3), 469–481 (2008).
   PubMed Web of Science ®Google Scholar
• Kress HG, Colberg T. Titration of intranasal fentanyl spray (INFS) for breakthrough pain in cancer patients: evidence for dose proportionality vs background analgesia. Eur. J. Pain13, S197 (2009).
   Google Scholar
• Mercadante S, Radbruch L, Davies A et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr. Med. Res. Opin.25(11), 2805–2815 (2009).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Burton AW, Gabrail N et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain151(3), 617–624 (2010).
   PubMed Web of Science ®Google Scholar
• Kress HG, Oronska A, Kaczmarek Z et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 µg for breakthrough pain in patients with cancer: a Phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin. Ther.31(6), 1177–1191 (2009).
   PubMed Web of Science ®Google Scholar
• Vissers D, Stam W, Nolte T et al. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr. Med. Res. Opin.26(5), 1037–1045 (2010).
   PubMed Web of Science ®Google Scholar
• Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH et al. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: a prospective, randomized, double-blind, placebo-controlled study. Clin. Ther.32(7), 1427–1436 (2010).
   PubMed Web of Science ®Google Scholar
• Younge PA, Nicole MF, Kendall JM. A prospective randomised pilot comparison of intranasal fentanyl and intramuscular morphine for analgesia in children presenting to the emergency department with clinical fractures. Emerg. Med. (Fremantle)11, 90–94 (1999).
   Google Scholar
• Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emerg. Med. (Fremantle)14(3), 275–280 (2002).
   PubMedGoogle Scholar
• Borland ML, Bergesio R, Pascoe EM et al. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns31(7), 831–837 (2005).
   PubMed Web of Science ®Google Scholar
• Borland M, Jacobs I, King B et al. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann. Emerg. Med.49(3), 335–340 (2007).
   PubMed Web of Science ®Google Scholar
• Borland ML, Clark LJ, Esson A. Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department. Emerg. Med. Australas.20(6), 515–520 (2008).
   PubMed Web of Science ®Google Scholar
• Chung S, Lim R, Goldman RD. Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography. Pediatr. Radiol.40(7), 1236–1240 (2010).
   PubMed Web of Science ®Google Scholar
• Crellin D, Ling RX, Babl FE. Does the standard intravenous solution of fentanyl (50 µg/ml) administered intranasally have analgesic efficacy? Emerg. Med. Australas.22(1), 62–67 (2010).
   PubMed Web of Science ®Google Scholar
• Cole J, Shepherd M, Young P. Intranasal fentanyl in 1–3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia. Emerg. Med. Australas.21(5), 395–400 (2009).
   PubMed Web of Science ®Google Scholar
• Herd D, Borland M. Intranasal fentanyl paediatric clinical practice guidelines. Emerg. Med. Australas.21(4), 335 (2009).
   PubMed Web of Science ®Google Scholar
• Fentanyl intranasal. Breakthrough cancer pain; unsafe packaging. Prescrire Int.19(110), 251 (2010).
   PubMedGoogle Scholar
• Nalamachu S, Narayana A, Janka L. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Curr. Med. Res. Opin.27(4), 751–760 (2011).
   PubMed Web of Science ®Google Scholar
• Wong S, Mundy L, Drake R et al. The prevalence of fentanyl in drug-related deaths in Philadelphia 2004–2006. J. Med Toxicol.6(1), 9–11 (2010).
   PubMedGoogle Scholar
• Center for Disease Control and Prevention (CDC). Nonpharmaceutical fentanyl-related deaths – multiple states, April 2005– March 2007. MMWR Morb. Mortal. Wkly Rep.57(29), 793–796 (2008).
   PubMedGoogle Scholar
• Schumann H, Erickson T, Thompson T et al. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin. Toxicol.46(6), 501–506 (2008).
   PubMed Web of Science ®Google Scholar
• Fodale V, Mafrica F, Santamaria L et al. Killer fentanyl: is the fear justified? Expert Opin. Drug Saf.7(3), 213–217 (2008).
   PubMed Web of Science ®Google Scholar
• Henderson G. Fentanyl-related deaths: demographics, circumstances, and toxicology of 112 cases. J. Forensic Sci.36(2), 422–433 (1991).
   PubMed Web of Science ®Google Scholar
• American Pharmacists Association. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patience access, medication safety, and impact on the health care system. J. Am. Pharm. Assoc.49(6), 729–743 (2003).
   Google Scholar